Former FDA Head Steve Hahn Joins BreakBio, a Personalized Cancer Drug Company, as Advisor
MIAMI, Oct. 26, 2026 /PRNewswire/ -- BreakBio, a biotech company developing personalized drugs for cancer, today announced that Stephen M....
DNA
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± chemotherapyCombinations demonstrated robust anti-tumor...
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy...
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with...
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores,...
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific...
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without...
Delta Dental Foundation of North Carolina Commits $1 Million to Expand Oral Health Access Statewide
Investments target children's and adult oral health and growing the workforce that makes access and dental care possible Delta Dental...
FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ETFocalTherics™ to Announce Third Quarter 2026...
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisionsTORONTO, Oct. 22,...
Foundation for Sarcoidosis Research Welcomes Nine New Members to the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA)
The FSR-GSCA unites 55 leading clinics worldwide in a powerful, shared commitment to advancing research, transforming patient care, and accelerating...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with...
Pharming Group announces third quarter 2026 revenues above market expectations
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total...
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an...
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated...
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 2026
New pipeline offers the potential to analyze up to 23 disease-associated repeat expansion loci in a single, low-cost runPROVIDENCE, R.I.,...
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening...
Pillar Biosciences and Collaborators to Present NGS Data Across Solid Tumors, Liquid Biopsy, and Heme Malignancies at 2026 Association for Molecular Pathology (AMP) Annual Meeting
NATICK, Mass., Oct. 15, 2026 /PRNewswire/ -- Pillar Biosciences today announced that ten scientific posters featuring their NGS technology will...
What’s More Space Age Than Spider Silk Spun by Kraig Labs’ Transgenic Silkworms?
DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Kraig Biocraft Laboratories (OTCQB: KBLB) shipped its first commercial spider silk...
Parexel to Spotlight Site Partnership, Innovation & Industry-Leading Site Performance at 2026 Society for Clinical Research Sites (SCRS) Global Site Solutions Summit™
Company brings its expertise in driving faster site activation and enrollment and better patient retention to panel discussions; continues commitment...